Table 5 Clinical characteristics of Crohn's disease patients in function of the amount of positive antibodies against gASCA, ALCA, ACCA, AMCA and Omp.
| No. of antibodies against tested microbial antigens | p trend | OR (95% CI) of O vs 4/5 | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 (n = 164) (%) | 1 (n = 236) (%) | 2 (n = 156) (%) | 3 (n = 118) (%) | 4 (n = 51) (%) | 5 (n = 13) (%) | |||
| Ileal involvement (%) | 69.5 | 82.6 | 86.5 | 89.8 | 88.2 | 92.3 | <0.001 | 3.57 (1.52 to 8.38) |
| Complicated behaviour (%) | 40.9 | 58.5 | 71.2 | 81.4 | 78.4 | 92.3 | <0.001 | 6.27 (3.11 to 12.64) |
| Need for abdominal surgery (%) | 37.8 | 49.2 | 59.6 | 74.6 | 84.3 | 76.9 | <0.001 | 7.93 (3.85 to 16.32) |
| Ulcerative colitis‐like behaviour (%) | 18.9 | 9.7 | 5.8 | 4.2 | 3.9 | 0 | <0.001 | 0.14 (0.03 to 0.60) |
ACCA, Anti‐chitobioside carbohydrate antibody; ALCA, anti‐laminaribioside carbohydrate antibody; AMCA, anti‐mannobioside carbohydrate antibody; gASCA, anti‐Saccharomyces cerevisiae antibody; Omp, outer membrane porin.
P trend based on linear‐by‐linear association. OR and 95% CI are based on comparison between 164 Crohn's disease patients with the absence of antibody response and 64 Crohn's disease patients with antibodies to four or all five tested antigens.